| Bioactivity | INH1 specifically disrupts the Hec1/Nek2 interaction via direct Hec1 binding. INH1 shows promising cancer inhibition activity both in vitro and in vivo[1]. | ||||||||||||
| Invitro | INH1 (25 μM, 24 h) treatment resulted in reduced association of Hec1 with kinetochore and decrease of global Nek2 protein level[1].INH1 exhibits GI50 values of 10.5 μM (in MDA-MB-468 cells), 15 μM (in SKBR3 cells), 10.5 μM (in T47D cells), 20.5 μM (in MDA-MB-361 cells), 15 μM (in ZR-75-1 cells), 15 μM (in HBL 100 cells), 15.5 μM (in MDA-MB-435 cells), 11 μM (in HS578T cells) and 41 μM (in MCF10A cells), respectively[1].INH1 (5k) has an IC50 value of 176 nM in the dose-dependent transwell migration assays in MDA-MB-231 cells. INH1 (5k) substantially reduces cellular f-actin and prevented localization of fascin to actin-rich membrane protrusions[2].INH1 induces abnormal mitotic processes, as well as cell apoptosis[3]. Cell Cytotoxicity Assay[1] Cell Line: | ||||||||||||
| Name | INH1 | ||||||||||||
| CAS | 313553-47-8 | ||||||||||||
| Formula | C18H16N2OS | ||||||||||||
| Molar Mass | 308.40 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|